Isturisa (Osilodrostat Phosphate) Patent Expiration, LOE Window & CMS Spending
Isturisa (Osilodrostat Phosphate) by Recordati Rare Diseases: FDA Orange Book core substance LOE 2033-05-20 (last listed 2035-10-12), 0 AB generics, $82.6M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Recordati Rare Diseases |
| FDA Application & Pathway | N212801 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2033-05-20 |
| Last Listed Patent or Exclusivity Date | 2035-10-12 |
| Orange Book Patents (*PED Extensions) | 7 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $82.6M |
| 2024 Medicare Part D Spend | $65.5M |
| 2024 Medicaid Spend | $17.1M |
| Reported Wholesale Price Change (CA SB 17) | 16 WAC filings (max 103.5% 2-yr change) |